Balyasny Asset Management L.P. Boosts Stake in Stevanato Group S.p.A. (NYSE:STVN)

Balyasny Asset Management L.P. grew its position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 14.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 186,447 shares of the company's stock after buying an additional 23,230 shares during the period. Balyasny Asset Management L.P. owned 0.06% of Stevanato Group worth $4,063,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. TimesSquare Capital Management LLC lifted its holdings in Stevanato Group by 114.6% during the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company's stock worth $71,657,000 after purchasing an additional 1,756,100 shares in the last quarter. Jennison Associates LLC bought a new position in shares of Stevanato Group during the 4th quarter valued at about $20,239,000. Mutual of America Capital Management LLC bought a new position in shares of Stevanato Group during the 4th quarter valued at about $13,848,000. Ranger Investment Management L.P. bought a new position in Stevanato Group during the 4th quarter worth approximately $12,940,000. Finally, Artisan Partners Limited Partnership grew its position in Stevanato Group by 28.7% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company's stock worth $51,333,000 after acquiring an additional 524,989 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on STVN shares. William Blair reiterated an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. UBS Group lowered their price objective on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a research note on Friday, March 7th. Finally, Stephens upgraded shares of Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Stevanato Group has a consensus rating of "Moderate Buy" and an average target price of €25.70 ($28.88).

Stevanato Group Stock Performance

Shares of STVN traded up €0.31 ($0.35) during trading hours on Friday, hitting €23.63 ($26.55). The stock had a trading volume of 73,897 shares, compared to its average volume of 347,148. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a 12 month low of €16.56 ($18.61) and a 12 month high of €24.96 ($28.04). The firm has a market capitalization of $7.16 billion, a PE ratio of 50.28, a PEG ratio of 7.18 and a beta of 0.51. The stock has a fifty day moving average price of €21.35 and a 200 day moving average price of €21.14.

Stevanato Group (NYSE:STVN - Get Free Report) last released its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million for the quarter, compared to the consensus estimate of €346.26 million. Analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Stevanato Group Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be paid a dividend of $0.0613 per share. This is a boost from Stevanato Group's previous annual dividend of $0.05. This represents a yield of 0.3%. The ex-dividend date is Thursday, June 5th. Stevanato Group's payout ratio is presently 11.76%.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.